(BMS) has opted to in-license an immune-modulating drug candidate developed by clinical-stage artificial intelligence (AI)-powered pharmatech company .
The companies currently have two active partnerships focusing on various therapeutic fields, such as oncology and immunology.
In 2019, Exscientia collaborated with Celgene, which was later acquired by BMS.
Exscientia and BMS signed a collaboration agreement in May to expand the 2019 alliance and facilitate multi-target, AI-powered drug discovery.
According to the deal, BMS will pay an option exercise fee of $20m to Exscientia, which is also eligible to receive potential development milestone payments, as well as tiered royalty payments on product sales.
BMS will also oversee the in-licensed drug candidate鈥檚 clinical and commercial development.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe candidate acts on a vital immunological kinase, which is traditionally proven as hard to target because of the requirements for potency, selectivity and total drug-like properties.
Exscientia leveraged its end-to-end platform to develop a new candidate with these characteristics.
The platform aided in the discovery process such as AI-powered design, structural biology, chemistry, and pharmacology, in addition to late-stage preclinical studies.
Exscientia鈥檚 precision design method focused on solving, in parallel, parameters vital to complete therapeutic performance for the target. This included potency, selectivity, safety, and physicochemical properties.
The company鈥檚 platform is well-suited for quickly and effectively resolving multi-objective design problems to discover new drug candidates with exceptional properties.
Exscientia CEO Andrew Hopkins said: 鈥淭his drug candidate molecule was just the 150th novel compound to be designed and tested and it was identified within 11 months of starting drug design.
鈥淚n partnership with Bristol Myers Squibb and its world-class research, clinical and commercialisation capabilities, we look forward to advancing this candidate into the next stage of development.鈥�
